Advertisement

Medical Treatment of Idiopathic Intracranial Hypertension (IIH)

  • Michael WallEmail author
Chapter

Abstract

Idiopathic intracranial hypertension (pseudotumor cerebri) is a disorder of elevated intracranial pressure of unknown cause. Patients present with headache, pulse synchronous tinnitus, transient visual obscurations, papilledema with its associated visual loss, and diplopia from VI nerve paresis. Many disease associations have been alleged but few other than obesity, hypervitaminosis A and related compounds, steroid withdrawal and female gender have been proven. The mainstays of medical treatment are use of a reduced-sodium weight-reduction (lifestyle management) program and acetazolamide. Adjunct medical treatments are topiramate and furosemide along with symptomatic headache treatments such as naproxen and amitriptyline. Treatment decisions are based primarily on the degree and progression of visual loss and severity of papilledema. Surgical treatments are employed for IIH patients that fail medical therapy.

Keywords

Idiopathic intracranial hypertension Pseudotumor cerebri Acetazolamide Weight loss 

References

  1. 1.
    Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. J Am Med Assoc. 2014;311(16):1641–51.CrossRefGoogle Scholar
  2. 2.
    Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol. 1988;45:866–72.CrossRefGoogle Scholar
  3. 3.
    Ireland B, Corbett JJ, Wallace RB. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol. 1990;47:315–20.CrossRefGoogle Scholar
  4. 4.
    Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology. 1991;41:239–44.CrossRefGoogle Scholar
  5. 5.
    Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010;28(3):593–617.CrossRefGoogle Scholar
  6. 6.
    Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med. 1974;133:802–7.CrossRefGoogle Scholar
  7. 7.
    Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105:2313–7.CrossRefGoogle Scholar
  8. 8.
    Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998;50:1094–8.CrossRefGoogle Scholar
  9. 9.
    Wong R, Madill SA, Pandey P, Riordan-Eva P. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol. 2007;7:15.CrossRefGoogle Scholar
  10. 10.
    Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.CrossRefGoogle Scholar
  11. 11.
    Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain. 1991;114:155–80.CrossRefGoogle Scholar
  12. 12.
    Johnston I, Paterson A. Benign intracranial hypertension. II. CSF pressure and circulation. Brain. 1974;97:301–12.CrossRefGoogle Scholar
  13. 13.
    Scoffings DJ, Pickard JD, Higgins JN. Resolution of transverse sinus stenoses immediately after CSF withdrawal in idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2007;78:911–2.CrossRefGoogle Scholar
  14. 14.
    McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on CSF production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther. 1974;189:194–201.PubMedGoogle Scholar
  15. 15.
    Zimran A, Beutler E. Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Am J Ophthalmol. 1987;104:654–8.CrossRefGoogle Scholar
  16. 16.
    Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116:322–7.CrossRefGoogle Scholar
  17. 17.
    Shah VA, Fung S, Shahbaz R, Taktakishvili O, Wall M, Lee AG. Idiopathic intracranial hypertension. Ophthalmology. 2007;114:617.CrossRefGoogle Scholar
  18. 18.
    Corbett JJ. The 1982 Silversides lecture. Problems in the diagnosis and treatment of pseudotumor cerebri. Can J Neurol Sci. 1983;10:221–9.CrossRefGoogle Scholar
  19. 19.
    Pollay M, Fullenwider C, Roberts PA, Stevens FA. Effect of mannitol and furosemide on blood-brain osmotic gradient and intracranial pressure. J Neurosurg. 1983;59:945–50.CrossRefGoogle Scholar
  20. 20.
    Schoeman J, Donald P, van Zyl L, Keet M, Wait J. Tuberculous hydrocephalus: comparison of different treatments with regard to ICP, ventricular size and clinical outcome. Dev Med Child Neurol. 1991;33:396–405.CrossRefGoogle Scholar
  21. 21.
    Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol. 1994;9:130–4.CrossRefGoogle Scholar
  22. 22.
    McGirt MJ, Woodworth G, Thomas G, Miller N, Williams M, Rigamonti D. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg. 2004;101(4):627–32.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Departments of Neurology and OphthalmologyUniversity of Iowa Carver College of MedicineIowa CityUSA
  2. 2.U.S. Department of Veterans AffairsWashington, DCUSA

Personalised recommendations